Amgen's revenue per share for the
three
months ended in Dec. 2023 was CHF12.26.
Amgen's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF43.64.
Good Sign:
Amgen Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of Amgen was 7.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 6.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 8.00% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 8.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Amgen's Revenue per Share or its related term are showing as below:
XSWX:AMGN'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.8 Med: 15.1 Max: 121.7
Current: 6.7
During the past 13 years, Amgen's highest 3-Year average Revenue Per Share Growth Rate was 121.70% per year. The lowest was 5.80% per year. And the median was 15.10% per year.
XSWX:AMGN's 3-Year Revenue Growth Rate is ranked better than 51.57% of 923
companies
in the Drug Manufacturers industry
Industry Median: 6.4
vs XSWX:AMGN: 6.70
Amgen Revenue per Share Historical Data
The historical data trend for Amgen's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amgen's Revenue per Share
For the Drug Manufacturers - General subindustry, Amgen's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's PS Ratio distribution charts can be found below:
* The bar in red indicates where Amgen's PS Ratio falls into.
Amgen Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Amgen's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF43.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (XSWX:AMGN) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Amgen Revenue per Share Related Terms
Thank you for viewing the detailed overview of Amgen's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:AMGN has been successfully added to your 